Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 10, 2005, Pages 1118-1123

  Herrmann, Markus ^a   Kraenzlin, Marius ^b   Pape, Gerhard ^a   Sand Hill, Marga ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bone mineral density; Bone turnover markers; Cross links; Desoxypyridinoline; Homocysteine; Osteocalcin

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; DEOXYPYRIDINOLINE; HOMOCYSTEINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLIMACTERIUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; MEDICAL EXAMINATION; MENOPAUSE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT CODING; POSTMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; URINALYSIS; VENOUS BLOOD;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIUM; FEMALE; HOMOCYSTINE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PERIMENOPAUSE; POSTMENOPAUSE; RISK FACTORS;

EID: 27744567341     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.195     Document Type: Article

References (37)

1. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12: 24-35.
2. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003; 18:1139-41.
3. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
4. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-86.
5. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765-7.
6. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14:411-5.
7. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
8. Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 2004;19:1969-75.
9. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
10. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.
11. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
12. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. J Am Med Assoc 2005;293:1082-8.
13. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003;33:956-9.
14. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004;35:760-5.
15. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37: 234-42,
16. Lenchik L, Kiebzak GIVI, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 2002;5(Suppl):S29-38.
17. Bonnick SL. Current controversies in bone densitometry. Curr Opin Rheumatol 2002;14:416-20.
18. Deal CL. Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep 2001;3:233-9.
19. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11 (Suppl 6):S2-17.
20. Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000;11(Suppl 6):S45-54.
21. Bode MK, Laitinen P, Risteli J, Uusimaa P, Juvonen T. Atherosclerosis, type 1 collagen cross-linking and homocysteine. Atherosclerosis 2000;152:531-2.
22. Miyao M, Morita H, Hosoi T, Kurihara H, Inoue S, Hoshino S, et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif Tissue Int 2000;66:190-4.
23. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005;20:921-9.
24. Njeh CF, Apple K, Temperton DH, Boivin CM. Radiological assessment of a new bone densitometer - the Lunar EXPERT. Br J Radiol 1996;69:335-40.
25. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidlines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999;21:1025-44.
26. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. J Am Med Assoc 2002;288:1889-97.
27. Grieco AJ. Homocystinuria: pathogenetic mechanisms. Am J Med Sci 1977;273:120-32.
28. Morreels CL Jr, Fletcher BID, Weilbaecher RG, Dorst JP. The roentgenographic features of homocystinuria. Radiology 1968;90:1150-8.
29. Mudd SH, Skovby F, Levy HL, Pettigrew KID, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
30. McKusick V. Heritable disorders of connective tissue, 3rd ed. St Louis, MO: Mosby, 2004,
31. Kang AH, Trelstad RL. A collagen defect in homocystinuria. J Clin Invest 1973;52:2571-8.
32. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-62.
33. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of elevated homocysteine levels. Clin Chem. In press.
34. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004;4:268-75.
35. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc 2004;292:490-5.
36. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
37. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5,